When Abiraterone Stops Working: — Resistance and What Comes Next

It may have limited benefit. Abiraterone and enzalutamide act on the same molecular pathway, and resistance to one frequently reduces the effectiveness of the other — a phenomenon called cross-resistance. NCCN guidance does not routinely recommend switching directly between them when one has stopped working. Your oncologist will assess your specific situation, but if your biomarker results point toward PARP inhibitors, PSMA therapy, or chemotherapy, those are usually the stronger directions to explore.

No. Resistance to abiraterone means one treatment has stopped working — not that treatment as a whole has. Several further lines of therapy have evidence in this setting, including chemotherapy, PARP inhibitors for those with qualifying gene mutations, and PSMA-targeted therapy for those whose disease expresses the PSMA protein. NCCN and ESMO guidance identifies these as active options, not end-of-care decisions. How many apply to you depends on your biomarker results, prior treatments, and current fitness.

The two most important questions to raise are: whether you have been tested for faults in BRCA1, BRCA2, or related DNA repair genes; and whether a PSMA PET scan is appropriate. The first tells your oncologist whether PARP inhibitors are a realistic option. The second maps whether PSMA-targeted therapy is suitable. ESMO recommends that germline and somatic gene testing be offered to all men with metastatic prostate cancer, not only those with a family history, because the result may only be discovered through testing.

There is rarely a reason to decide in days. Confirming resistance, obtaining biomarker results that may not yet be available, and understanding what each option actually involves takes time — and the decision is better made with that information than without it. Your oncologist will tell you if the pace of progression means something more urgent is needed. If you are unsure what is driving the timeline, ask: you are entitled to a clear answer about whether there is genuine urgency.

Restarting abiraterone after confirmed resistance — sometimes called re-challenge — is not supported by NCCN or ASCO guidance as a standard approach. The molecular changes that cause resistance tend to be durable rather than reversible. Returning to a treatment that has stopped working is generally not the best use of the time and side-effect burden it would involve. Your oncologist will direct you toward options where there is better evidence of benefit in your specific situation.

Clinical trials are always worth asking about. They are not a last resort — some trials provide access to treatments not yet routinely available, and they are often the fastest route to newer options. Your oncologist can tell you whether any relevant trials are open at CION centres or elsewhere. A second opinion is also reasonable to seek at any stage: knowing that another oncologist would approach this the same way — or differently — is useful, and asking for one should not affect your care.